# OnCo record egl-001 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/egl-001/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "egl-001" ;
  schema:name "EGL-001"@en ;
  schema:alternateName "anti-CTLA-4-IL-2m"@en ;
  schema:description "EGL-001 is an experimental immunocytokine: anti-CTLA-4 antibody fused to an IL-2 mutein from Egle Therapeutics, in phase 1 trials for advanced solid tumours and head and neck squamous cell carcinoma."@en ;
  schema:url <https://onco.cc/drugs/egl-001/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.egle-tx.com/>, <https://www.egle-tx.com/egle-therapeutics-and-consortium-partners-awarded-e8-million-grant-from-horizon-europe-to-advance-clinical-development-of-egl-001-in-neoadjuvant-head-and-neck-cancer/>, <https://clinicaltrials.gov/api/v2/studies/NCT06622486>, <https://clinicaltrials.gov/search?intr=EGL-001> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Immunocytokine: anti-CTLA-4 antibody fused to an IL-2 mutein" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:targets <https://onco.cc/targets/ctla4/> ;
  onco:companies <https://onco.cc/companies/egle-therapeutics/> ;
  onco:trials <https://onco.cc/trials/nct06622486/> .